Header Logo

Connection

CHING-WEI DAVID TZENG to Carcinoma, Pancreatic Ductal

Back to Details
This is a "connection" page, showing publications CHING-WEI DAVID TZENG has written about Carcinoma, Pancreatic Ductal.
CHING-WEI DAVID TZENG
Connection Strength
6.571
Carcinoma, Pancreatic Ductal
  1. Prognosis Associated With CA19-9 Response Dynamics and Normalization During Neoadjuvant Therapy in Resected Pancreatic Adenocarcinoma. Ann Surg. 2023 03 01; 277(3):484-490.
    View in: PubMed
    Score: 0.387
  2. Prognostic significance of preoperative and postoperative CA 19-9 normalization in pancreatic adenocarcinoma treated with neoadjuvant therapy or surgery first. J Surg Oncol. 2022 Nov; 126(6):1021-1027.
    View in: PubMed
    Score: 0.374
  3. Perioperative blood transfusions and survival in resected pancreatic adenocarcinoma patients given multimodality therapy. J Surg Oncol. 2021 Dec; 124(8):1381-1389.
    View in: PubMed
    Score: 0.352
  4. ASO Author Reflections: Potential Role of Circulating Biomarkers in Resected Pancreatic Adenocarcinoma. Ann Surg Oncol. 2021 Aug; 28(8):4623-4624.
    View in: PubMed
    Score: 0.339
  5. Measurement of Portal Vein Blood Circulating Tumor Cells is Safe and May Correlate With Outcomes in Resected Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol. 2021 Aug; 28(8):4615-4622.
    View in: PubMed
    Score: 0.338
  6. ASO Author Reflections: Tumor Biology and Safe Surgery Remain Major Determinants of Survival After Resection of Pancreatic Adenocarcinoma. Ann Surg Oncol. 2021 Mar; 28(3):1570-1571.
    View in: PubMed
    Score: 0.330
  7. Impact of Intraoperative Dexamethasone on Surgical and Oncologic Outcomes for Patients with Resected Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol. 2021 Mar; 28(3):1563-1569.
    View in: PubMed
    Score: 0.329
  8. Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIRINOX. Pancreas. 2019 07; 48(6):837-843.
    View in: PubMed
    Score: 0.304
  9. Circulating Tumor Cells and Transforming Growth Factor Beta in Resected Pancreatic Adenocarcinoma. J Surg Res. 2019 11; 243:90-99.
    View in: PubMed
    Score: 0.303
  10. Is early-stage pancreatic adenocarcinoma truly early: stage migration on final pathology with surgery-first versus neoadjuvant therapy sequencing. HPB (Oxford). 2019 09; 21(9):1203-1210.
    View in: PubMed
    Score: 0.297
  11. Perioperative blood transfusions for vein resection during pancreaticoduodenectomy for pancreatic adenocarcinoma: Identification of clinical targets for optimization. HPB (Oxford). 2019 07; 21(7):841-848.
    View in: PubMed
    Score: 0.292
  12. Effect of complications on oncologic outcomes after pancreaticoduodenectomy for pancreatic cancer. J Surg Res. 2017 06 15; 214:1-8.
    View in: PubMed
    Score: 0.260
  13. Defining the optimal timing of adjuvant therapy for resected pancreatic adenocarcinoma: A statewide cancer registry analysis. J Surg Oncol. 2016 Sep; 114(4):451-5.
    View in: PubMed
    Score: 0.246
  14. Effect of surgical approach on early return to intended oncologic therapy after resection for pancreatic ductal adenocarcinoma. Surg Endosc. 2024 Sep; 38(9):4986-4995.
    View in: PubMed
    Score: 0.108
  15. Improved Clinical Staging System for Localized Pancreatic Cancer Using the ABC Factors: A TAPS Consortium Study. J Clin Oncol. 2024 Apr 20; 42(12):1357-1367.
    View in: PubMed
    Score: 0.105
  16. Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. J Immunother Cancer. 2024 Feb 02; 12(2).
    View in: PubMed
    Score: 0.105
  17. Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial. Lancet Oncol. 2023 12; 24(12):1387-1398.
    View in: PubMed
    Score: 0.103
  18. Integrated Pathologic Score Effectively Stratifies Patients With Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant Therapy and Pancreaticoduodenectomy. Am J Surg Pathol. 2023 04 01; 47(4):421-430.
    View in: PubMed
    Score: 0.098
  19. 3D imaging analysis on an organoid-based platform guides personalized treatment in pancreatic ductal adenocarcinoma. J Clin Invest. 2022 12 15; 132(24).
    View in: PubMed
    Score: 0.097
  20. Incidence of Postoperative Complications Following Pancreatectomy for Pancreatic Cystic Lesions or Pancreatic Cancer. J Gastrointest Surg. 2023 02; 27(2):319-327.
    View in: PubMed
    Score: 0.096
  21. Single-Cell Sequencing Reveals Trajectory of Tumor-Infiltrating Lymphocyte States in Pancreatic Cancer. Cancer Discov. 2022 10 05; 12(10):2330-2349.
    View in: PubMed
    Score: 0.095
  22. Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer: Phase 1 Trial and Imaging-based Biomarker Validation. Int J Radiat Oncol Biol Phys. 2022 11 01; 114(3):444-453.
    View in: PubMed
    Score: 0.094
  23. Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study. J Natl Compr Canc Netw. 2022 07; 20(7):783-791.e1.
    View in: PubMed
    Score: 0.094
  24. FOLFIRINOX as Initial Treatment for Localized Pancreatic Adenocarcinoma: A Retrospective Analysis by the Trans-Atlantic Pancreatic Surgery Consortium. J Natl Cancer Inst. 2022 05 09; 114(5):695-703.
    View in: PubMed
    Score: 0.093
  25. GRP78 expression and prognostic significance in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant therapy versus surgery first. Pancreatology. 2021 Oct; 21(7):1378-1385.
    View in: PubMed
    Score: 0.088
  26. Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients. Cancer Med. 2021 08; 10(15):5041-5050.
    View in: PubMed
    Score: 0.088
  27. History of preoperative therapy for pancreatic cancer and the MD Anderson experience. J Surg Oncol. 2021 May; 123(6):1414-1422.
    View in: PubMed
    Score: 0.086
  28. Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer. Ann Surg. 2021 04 01; 273(4):806-813.
    View in: PubMed
    Score: 0.086
  29. Overexpression of CD73 in pancreatic ductal adenocarcinoma is associated with immunosuppressive tumor microenvironment and poor survival. Pancreatology. 2021 Aug; 21(5):942-949.
    View in: PubMed
    Score: 0.086
  30. Clinicopathological correlation of radiologic measurement of post-therapy tumor size and tumor volume for pancreatic ductal adenocarcinoma. Pancreatology. 2021 Jan; 21(1):200-207.
    View in: PubMed
    Score: 0.084
  31. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. JAMA Surg. 2020 09 01; 155(9):832-839.
    View in: PubMed
    Score: 0.082
  32. Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes. Cell. 2019 08 08; 178(4):795-806.e12.
    View in: PubMed
    Score: 0.077
  33. Chemotherapy Versus Chemoradiation as Preoperative Therapy for Resectable Pancreatic Ductal Adenocarcinoma: A Propensity Score Adjusted Analysis. Pancreas. 2019 02; 48(2):216-222.
    View in: PubMed
    Score: 0.074
  34. Single-Cell Transcriptomics of Pancreatic Cancer Precursors Demonstrates Epithelial and Microenvironmental Heterogeneity as an Early Event in Neoplastic Progression. Clin Cancer Res. 2019 Apr 01; 25(7):2194-2205.
    View in: PubMed
    Score: 0.073
  35. First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol. 2019 Feb; 26(2):619-627.
    View in: PubMed
    Score: 0.072
  36. The role of preoperative therapy prior to pancreatoduodenectomy for distal cholangiocarcinoma. Am J Surg. 2019 07; 218(1):145-150.
    View in: PubMed
    Score: 0.072
  37. Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy. Cancer. 2018 04 15; 124(8):1701-1709.
    View in: PubMed
    Score: 0.069
  38. Anthropometric Changes in Patients with Pancreatic Cancer Undergoing Preoperative Therapy and Pancreatoduodenectomy. J Gastrointest Surg. 2018 04; 22(4):703-712.
    View in: PubMed
    Score: 0.068
  39. Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma. JAMA Surg. 2017 Nov 01; 152(11):1048-1056.
    View in: PubMed
    Score: 0.068
  40. The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative Therapy. Ann Surg Oncol. 2015 Dec; 22 Suppl 3:S1221-8.
    View in: PubMed
    Score: 0.058
  41. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study. Acta Oncol. 2016; 55(3):265-77.
    View in: PubMed
    Score: 0.058
  42. Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy. Ann Surg Oncol. 2012 Jun; 19(6):2045-53.
    View in: PubMed
    Score: 0.045
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.